With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3030-47-5,N1-(2-(Dimethylamino)ethyl)-N1,N2,N2-trimethylethane-1,2-diamine,as a common compound, the synthetic route is as follows.
The ligand pmdien (0.2 ml, 1 mmol) was added to a stirred solutionof Ni(ClO4)2*6H2O (0.36 g, 1 mmol) in methanol (35 ml). The colour of solution turned to violet. Solution of tdaH2 (0.075 g,0.5 mmol) neutralized with KOH (0.056 g, 1 mmol) in water (5 ml) was added. Violet colour turned to green and after a while white precipitate was formed. Precipitate was removed by filtration and filtrate was left for crystallization. After a week green crystals (suitable for X-ray analyses) were collected on a frit funnel, washed with methanol and dried in air., 3030-47-5
3030-47-5 N1-(2-(Dimethylamino)ethyl)-N1,N2,N2-trimethylethane-1,2-diamine 18196, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Article; Bie?ko, Alina; Kopel, Pavel; Kizek, Rene; Kruszy?ski, Rafa?; Bie?ko, Dariusz; Titi?, Jan; Bo?a, Roman; Inorganica Chimica Acta; vol. 416; (2014); p. 147 – 156;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI